Crossmark

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-018-4829-4

Published Online: 2018-06-27

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brennan, Meghan

Gass, Paul

Häberle, Lothar

Wang, Daidong

Hartmann, Arndt

Lux, Michael P.

Beckmann, Matthias W.

Untch, Michael

Fasching, Peter A.
License Information

Text and Data Mining valid from 2018-06-27
More Information

Article History

Received: 4 December 2017

Accepted: 6 February 2018

First Online: 27 June 2018

Compliance with ethical standards

:

: PAF reports to have received honoraria from Amgen, Novartis, Pfizer, Celgene, Genomic Health, and Nanostring. PAF’s institution conducts research sponsored by Novartis, Amgen, and Celgene.